Goldenwell BIOTECH, Inc. (GWLL) intrinsic value & 10-year financials
Goldenwell BIOTECH, Inc. (GWLL) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue shrank 79.4% a year to $139, with an average return on invested capital of -283.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.60
- Market cap
- $59.4M
- Revenue (FY2024)
- $139
- Revenue growth (7-yr CAGR)
- -79.4%
- ROIC (10-yr avg)
- -283.0%
- Free cash flow (FY2024)
- —
GWLL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | $139 | -$131.5K | $0.00 | — | -88559.7% | -158.7% |
| FY2023 | $2.3K | -$116.9K | $0.00 | — | -4995.5% | -150.2% |
| FY2022 | $47.8K | -$985.1K | — | — | -2060.9% | -1117.4% |
| FY2021 | $16.0K | -$117.0K | — | — | -740.7% | -268.3% |
| FY2020 | $0 | -$6.3K | — | — | — | -2.6% |
| FY2019 | $0 | -$2.3K | — | — | — | -0.9% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
GOLDENWELL BIOTECH, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
GOLDENWELL BIOTECH, INC. has historically struggled to out-earn its cost of capital, averaging just -3.4% ROIC.
GOLDENWELL BIOTECH, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, GOLDENWELL BIOTECH, INC. is modeled at -79.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.00 per share.